A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- Registry ID
- B1481021
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- PFIZER CANADA INC
- Start date
- 2014-06-23
- Last update
- 2014-05-16
Conditions
- HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Related clinical trials
- A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFECT OF AZD0780 ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA
- OPEN-LABEL, PHASE LB, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY OF
VERVE-102 ADMINISTERED TO PATIENTS WITH HETEROZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA OR PREMATURE CORONARY ARTERY DISEASE WHO REQUIRE ADDITIONAL
LOWERING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL
- AN 8-WEEK OPEN-LABEL, SEQUENTIAL, REPEATED DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AIIROCUMAB IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA FOLLOWED BY AN EXTENSION PHASE
- DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO CHARACTERIZE THE EFFICACY, SAFETY AND TOLERABLITY OF 24 WEEKS OF EVOLOCUMAB FOR LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LSL-C) REDUCTION, AS ADD-ON TO DIET AND LIPID-LOWERING THERAPY, IN PEDIATRIC SUBJECTS 10 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, CROSS-OVER STUDY OF ROSUVASTATIN IN CHILDREN AND ADOLESCENTS (AGED 6 TO <18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
View on source registry